MANKIND PHARMA LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,140 INR | +2.18% |
|
+3.73% | +7.93% |
| 05-30 | Advent International Receives 6-7 Bids for Bharat Serums | CI |
| 05-16 | Transcript : Mankind Pharma Limited, Q4 2024 Earnings Call, May 16, 2024 |
Valuation
| Fiscal Period: March | 2024 | 2025 | 2026 |
|---|---|---|---|
| Capitalization 1 | 857,259 | - | - |
| Enterprise Value (EV) 1 | 921,654 | 813,713 | 792,071 |
| P/E ratio | 48.3 x | 38.8 x | 32.6 x |
| Yield | 0.29% | 0.41% | 0.52% |
| Capitalization / Revenue | 8.92 x | 7.37 x | 6.5 x |
| EV / Revenue | 8.92 x | 6.99 x | 6.01 x |
| EV / EBITDA | 36.4 x | 27.6 x | 23 x |
| EV / FCF | 55.9 x | 44.1 x | 35.7 x |
| FCF Yield | 1.79% | 2.27% | 2.8% |
| Price to Book | 9.27 x | 7.41 x | 6.14 x |
| Nbr of stocks (in thousands) | 400,635 | - | - |
| Reference price 2 | 2,140 | 2,140 | 2,140 |
| Announcement Date | 24-05-15 | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 87,494 | 103,348 | 116,335 | 131,808 |
| EBITDA 1 | - | 19,006 | 25,351 | 29,513 | 34,400 |
| EBIT 1 | - | 15,747 | 21,368 | 25,339 | 29,832 |
| Operating Margin | - | 18% | 20.68% | 21.78% | 22.63% |
| Earnings before Tax (EBT) 1 | - | 16,712 | 23,994 | 27,887 | 33,115 |
| Net income 1 | 14,335 | 12,819 | 19,129 | 22,084 | 26,342 |
| Net margin | - | 14.65% | 18.51% | 18.98% | 19.98% |
| EPS 2 | 35.78 | 32.00 | 47.68 | 55.10 | 65.71 |
| Free Cash Flow 1 | - | 10,243 | 14,885 | 18,467 | 22,188 |
| FCF margin | - | 11.71% | 14.43% | 15.87% | 16.83% |
| FCF Conversion (EBITDA) | - | 53.89% | 59.7% | 62.57% | 64.5% |
| FCF Conversion (Net income) | - | 79.91% | 81.35% | 83.62% | 84.23% |
| Dividend per Share 2 | - | - | 6.200 | 8.714 | 11.18 |
| Announcement Date | 22-08-01 | 23-05-30 | 24-05-15 | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|
| Net sales 1 | 25,786 | 26,998 | 24,214 | 24,228 |
| EBITDA 1 | 6,548 | 6,987 | 5,822 | 5,585 |
| EBIT 1 | 5,675 | 5,706 | 4,347 | 4,155 |
| Operating Margin | 22.01% | 21.13% | 17.95% | 17.15% |
| Earnings before Tax (EBT) 1 | 6,245 | 6,229 | 4,984 | 4,776 |
| Net income 1 | 4,869 | 5,176 | 4,194 | 3,823 |
| Net margin | 18.88% | 19.17% | 17.32% | 15.78% |
| EPS 2 | 12.14 | 11.00 | 9.867 | 9.350 |
| Dividend per Share | - | - | - | - |
| Announcement Date | 23-08-02 | - | - | - |
1INR in Million2INR
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | - | - | 25,253 | 43,546 | 65,188 |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | 10,243 | 14,885 | 18,467 | 22,188 |
| ROE (net income / shareholders' equity) | - | 18.9% | 21.4% | 21.3% | 21% |
| ROA (Net income/ Total Assets) | - | 13.6% | 17.4% | 18.5% | 18% |
| Assets 1 | - | 94,317 | 105,405 | 119,461 | 146,299 |
| Book Value Per Share 2 | - | 186.0 | 231.0 | 289.0 | 349.0 |
| Cash Flow per Share 2 | - | 45.30 | 54.90 | 65.40 | 76.70 |
| Capex 1 | - | 7,890 | 4,983 | 4,907 | 5,235 |
| Capex / Sales | - | 9.02% | 4.83% | 4.22% | 3.97% |
| Announcement Date | 22-08-01 | 23-05-30 | 24-05-15 | - | - |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
2,140
INR
Average target price
2,237
INR
Spread / Average Target
+4.54%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +7.93% | 10.27B | |
| +40.73% | 739B | |
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| +9.78% | 210B | |
| -5.52% | 206B | |
| +6.17% | 164B |
- Stock Market
- Equities
- MANKIND Stock
- Financials Mankind Pharma Limited
